SG11202107589PA - Rodents having genetically modified sodium channels and methods of use thereof - Google Patents

Rodents having genetically modified sodium channels and methods of use thereof

Info

Publication number
SG11202107589PA
SG11202107589PA SG11202107589PA SG11202107589PA SG11202107589PA SG 11202107589P A SG11202107589P A SG 11202107589PA SG 11202107589P A SG11202107589P A SG 11202107589PA SG 11202107589P A SG11202107589P A SG 11202107589PA SG 11202107589P A SG11202107589P A SG 11202107589PA
Authority
SG
Singapore
Prior art keywords
rodents
methods
genetically modified
sodium channels
modified sodium
Prior art date
Application number
SG11202107589PA
Other languages
English (en)
Inventor
Nicole Alessandri-Haber
Andrew J Murphy
Lynn Macdonald
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of SG11202107589PA publication Critical patent/SG11202107589PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202107589PA 2019-02-22 2020-02-21 Rodents having genetically modified sodium channels and methods of use thereof SG11202107589PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808957P 2019-02-22 2019-02-22
PCT/US2020/019171 WO2020172505A1 (en) 2019-02-22 2020-02-21 Rodents having genetically modified sodium channels and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202107589PA true SG11202107589PA (en) 2021-08-30

Family

ID=70005744

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107589PA SG11202107589PA (en) 2019-02-22 2020-02-21 Rodents having genetically modified sodium channels and methods of use thereof

Country Status (12)

Country Link
US (1) US11464217B2 (pt)
EP (1) EP3927153A1 (pt)
JP (1) JP2022520819A (pt)
KR (1) KR20210129083A (pt)
CN (1) CN113473850A (pt)
AU (1) AU2020226865A1 (pt)
BR (1) BR112021016173A2 (pt)
CA (1) CA3127153A1 (pt)
IL (1) IL285663A (pt)
MX (1) MX2021009855A (pt)
SG (1) SG11202107589PA (pt)
WO (1) WO2020172505A1 (pt)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
KR101559769B1 (ko) 2008-03-19 2015-10-13 엘지전자 주식회사 미들웨어, 녹화물 목록 제공 방법 및 녹화물 목록 제공방법을 기록한 기록매체
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US8658154B2 (en) 2009-12-21 2014-02-25 Regeneron Pharmaceuticals, Inc. Humanized FcγR mice
BR122014002928A2 (pt) 2010-02-08 2015-12-29 Regeneron Pharma métodos de produzir um camundongo e um anticorpo e de selecionar uma região variável de cadeia pesada humana para a produção de uma proteína de ligação ao antígeno, uso de um camundongo geneticamente modificado na produção de uma proteína de ligação ao antígeno, bem como anticorpo quimérico e hibridoma
US20130185821A1 (en) 2010-02-08 2013-07-18 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
BR122020013427B1 (pt) 2010-06-22 2021-08-03 Regeneron Pharmaceuticals, Inc Método para fazer um camundongo, uma célula ou tecido derivado de um camundongo e um hibridoma
CN103429746B (zh) 2011-02-25 2016-05-11 瑞泽恩制药公司 Adam6小鼠
US20130115171A1 (en) * 2011-11-09 2013-05-09 Stefan I. McDonough Nav1.7-related assays
SG11201405088QA (en) 2012-03-06 2014-11-27 Regeneron Pharma Common light chain mouse
JP2015525071A (ja) 2012-06-05 2015-09-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖を用いて完全ヒト型二重特異性抗体を作製するための方法
SG11201505968WA (en) 2013-02-20 2015-08-28 Regeneron Pharma Genetic modification of rats
CN105189545A (zh) 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
BR112015022034B1 (pt) 2013-03-13 2023-02-28 Regeneron Pharmaceuticals, Inc Método de fabricar um camundongo, e, para fabricar um anticorpo
JP6533512B2 (ja) * 2013-03-14 2019-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎａｖ１．７に対するヒト抗体
SG11201508028QA (en) 2013-04-16 2015-10-29 Regeneron Pharma Targeted modification of rat genome
NZ726355A (en) 2014-05-30 2018-08-31 Regeneron Pharma Humanized dipeptidyl peptidase iv (dpp4) animals
US20170247436A1 (en) * 2016-02-16 2017-08-31 Regeneron Pharmaceuticals, Inc. Non-human animals having a mutant kynureninase gene
SG11201810757YA (en) * 2016-06-03 2018-12-28 Regeneron Pharma Non-human animals expressing exogenous terminal deoxynucleotidyltransferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
MA53935A (fr) 2016-11-04 2021-12-22 Regeneron Pharma Animaux non humains ayant un locus à chaîne légère lambda d'immunoglobuline modifiée
EP3644722A1 (en) 2017-06-27 2020-05-06 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized asgr1 locus
AU2018381316A1 (en) 2017-12-05 2020-04-23 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
TWI829679B (zh) 2018-03-26 2024-01-21 美商再生元醫藥公司 用於測試治療藥劑之人類化囓齒動物

Also Published As

Publication number Publication date
US20200267950A1 (en) 2020-08-27
KR20210129083A (ko) 2021-10-27
AU2020226865A1 (en) 2021-07-29
US11464217B2 (en) 2022-10-11
IL285663A (en) 2021-10-31
CN113473850A (zh) 2021-10-01
MX2021009855A (es) 2021-09-10
JP2022520819A (ja) 2022-04-01
EP3927153A1 (en) 2021-12-29
WO2020172505A1 (en) 2020-08-27
CA3127153A1 (en) 2020-08-27
BR112021016173A2 (pt) 2021-11-03

Similar Documents

Publication Publication Date Title
IL280709A (en) Converted indoles and methods of using them
IL290297A (en) Different cytotoxic t cells and methods of using them
IL289473A (en) Transgenic mammals and methods of use
IL276687A (en) Trialkyne coupling agents and methods of using them
IL276135A (en) Preparations and methods of use
IL287966A (en) Automatic injector and associated methods of use
IL289469A (en) Transgenic mammals and their methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
DK3517083T3 (da) Høreværnssystem og relateret fremgangsmåde
IL283782A (en) Analosomes and methods of use
IL291730A (en) Protein-macromolecule conjugates and methods for using them
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
IL280000A (en) Formulations for reducing tumors and methods of using them
IL280300A (en) Optimized cln7 genes and expression cassettes and their use
IL291360A (en) Benzimidazoles and methods of using them
SG11202112008PA (en) Chromophore-labeled oligosaccharide markers and methods of use thereof
IL291180A (en) Bee vaccines and methods of use
IL286485A (en) pi4-kinase inhibitors and methods of using them
IL282533A (en) Oligosaccharide preparations and methods of using them
ZA201908276B (en) Charge-tagged nucleotides and methods of use thereof
GB201915317D0 (en) Earmuff and headphone
IL285663A (en) Rodents with genetically engineered sodium channels and methods of using them
GB2589398B (en) Compounds and methods of use
IL287797A (en) Oligosaccharide preparations and methods of use
SG11202011121UA (en) Dantrolene formulations and methods of their use